DSM Pharmaceutical Products has extended its process development and manufacturing agreement with Agennix to include commercial manufacture of talactoferrin, an oral dendritic cell mediated immunotherapy.
Pharmaceutical Business Review
Wednesday 14 March 2012
DSM extends contract with Agennix
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment